Biogen Inc [BIIB] stock is trading at $148.76, up 1.75%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BIIB shares have gain 5.84% over the last week, with a monthly amount drifted -0.42%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on January 02, 2025, when Piper Sandler downgraded its rating to a Neutral and also revised its price target to $138 from $315. Previously, BMO Capital Markets downgraded its rating to Market Perform on December 20, 2024, and dropped its price target to $164. On December 16, 2024, downgrade downgraded it’s rating to Hold but maintained its price target of $175 on the stock. Jefferies downgraded its rating to a Hold and reduced its price target to $180 on December 09, 2024. Needham downgraded its rating to Hold for this stock on November 18, 2024. In a note dated November 15, 2024, Wolfe Research initiated an Peer Perform rating.
Biogen Inc [BIIB] stock has fluctuated between $139.71 and $251.99 over the past year. Currently, Wall Street analysts expect the stock to reach $242.33 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $148.76 at the most recent close of the market. An investor can expect a potential return of 62.9% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
Biogen Inc [NASDAQ:BIIB] reported sales of 9.23B for the trailing twelve months, which represents a drop of -2.44%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.1 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 146.98 points at the first support level, and at 145.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 150.10, and for the 2nd resistance point, it is at 151.44.
Ratios To Look Out For
For context, Biogen Inc’s Current Ratio is 1.26. Further, the Quick Ratio stands at 0.80, while the Cash Ratio is 0.31. Considering the valuation of this stock, the price to sales ratio is 2.35, the price to book ratio is 1.32 and price to earnings (TTM) ratio is 13.44.
Transactions by insiders
Recent insider trading involved Singhal Priya, Head of Development, that happened on Dec 09 ’24 when 110.0 shares were sold. Officer, Singhal Priya completed a deal on Dec 09 ’24 to buy 110.0 shares. Meanwhile, Head of Development Singhal Priya sold 431.0 shares on Sep 03 ’24.
